Hifibio Therapeutics, a platform player until now, has secured an oversubscribed $37.5 million series B financing aimed at helping it build its own pipeline of antibody therapies for cancer and autoimmune disorders. Meanwhile, the company will continue to form new strategic partnerships, it said, such as earlier-established tie-ups with Pfizer Inc. and Janssen Biotech Inc.